A global agenda for older adult immunization in the COVID-19 era: A roadmap for action
Authors:
- Lois A. Privor-DummLois A. Privor-Dumm
- Gregory A. PolandGPGregory A. Poland
- Jane BarrattJBJane Barratt
- David N. DurrheimDavid N. Durrheim
- Maria Deloria KnollMaria Deloria Knoll
- Prarthana VasudevanPVPrarthana Vasudevan
- Mark JitMark Jit
- Pablo E. BonvehíPBPablo E. Bonvehí
- Paolo BonanniPaolo Bonanni
- 1 August 2021
- Vol. 39 (37) , 5240-5250
Abstract
No abstract availableKeywords
Funding Information
- Merck
- National Institutes of Health
- Pfizer
This publication has 71 references indexed in Scilit:
- Influenza cost and cost-effectiveness studies globally – A reviewVaccine, 2013
- AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialThe Lancet Infectious Diseases, 2013
- Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adultsVaccine, 2011
- A policy framework for accelerating adoption of new vaccinesHuman Vaccines, 2010
- Effect of Influenza Vaccination of Children on Infection Rates in Hutterite CommunitiesJAMA, 2010
- The Effect of Universal Influenza Immunization on Antibiotic Prescriptions: An Ecological StudyClinical Infectious Diseases, 2009
- The Epidemiological, Clinical, and Pathological Rationale for the Herpes Zoster VaccineThe Journal of Infectious Diseases, 2008
- COPD exacerbations: defining their cause and preventionThe Lancet, 2007
- The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older AdultsThe Clinical Journal of Pain, 2007
- Infections and Functional Impairment in Nursing Home Residents: A Reciprocal RelationshipJournal of the American Geriatrics Society, 2004